APO 010 companion diagnostic - Oncology Venture

Drug Profile

APO 010 companion diagnostic - Oncology Venture

Alternative Names: APO010 DRP™

Latest Information Update: 11 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Oncology Venture
  • Developer Medical Prognosis Institute; Oncology Venture
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Multiple myeloma

Most Recent Events

  • 07 Oct 2016 Oncology Venture in-licenses Drug Response Prediction (DRP™) technology from Medical Prognosis Institute before October 2016 (Oncology Venture website, October 2016),
  • 07 Oct 2016 Phase-II clinical trials in Multiple myeloma (Diagnosis) in Denmark (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top